Monoclonal Antibodies Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 8.51 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Monoclonal Antibodies Market Analysis
The monoclonal antibodies market is expected to register a CAGR of 8.51% during the forecast period (2022-2027).
The monoclonal antibody production was halted due to the COVID-19 pandemic, and it severely affected the global monoclonal antibodies market as they are widely used in cancer and gene therapy, thus affecting the global monoclonal antibodies market. Although COVID-19 was at its peak in Europe and the United States in 2020, few companies were working on new therapy based on monoclonal antibodies to treat COVID-19. They isolated the COVID-19 antibodies from a recovered person and tested them as a cure for COVID-19 infection, and they were successful and got approval for emergency use by the United States Food and Drug Administration. For example, in February 2021, the Food and Drug Administration permitted emergency use of combined bamlanivimab and etesevimab therapy developed by Eli Lilly and Company for people with mild to moderate COVID-19 infection. Moreover, due to the potential application of monoclonal antibodies, it can be expected that COVID-19 will promote the monoclonal antibodies market.
The monoclonal antibodies are becoming ubiquitous in the treatment of different forms of cancer in developed countries, and this has been attributed to the rapid growth of the global monoclonal antibodies market. According to the report of GLOBOCAN 2020, there were 19.3 million new cases of cancer and about 10 million deaths due to cancer in the world, and increasing cancer cases are the major growth factor behind the market. The other factors, which may contribute positively toward the high growth of the global monoclonal antibodies market, are new gene-based therapy, new research related to the application of monoclonal antibodies in treating some other deadly diseases, like COVID-19, disease diagnostics, and treatment of other diseases, like auto-immune, viral disease treatment, and also the approval of new antibodies by governments may lead to the growth of the market. For instance, In January 2022, GlaxoSmithKline plc and Vir Biotechnology, Inc. announced that the United States government will purchase an additional 600,000 doses of sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, enabling further nationwide access to sotrovimab for patients.
The cost associating with monoclonal antibodies is very high because of their complex manufacturing procedure and due to the cost involved in R&D, and it is one of the major restraining factors for the growth of the global monoclonal antibodies market. The high cost of monoclonal antibodies is the main reason why it is still prevalent only in developed countries and not in developing and underdeveloped countries. Another factor responsible that can prove a restraint for this market will be the loss of patents by companies.
Monoclonal Antibodies Market Trends
This section covers the major market trends shaping the Monoclonal Antibodies Market according to our research experts:
Cancer Monoclonal Antibodies is Estimated to Occupy a Significant Share in the Market over the Forecast Period
Monoclonal antibodies are highly specific to cancer cells, as they bind to the proteins on their surface and stimulate an immune response. Due to the rising prevalence of cancer cases, globally, in the global monoclonal antibodies market, cancer monoclonal antibodies may occupy a major market share. The number of people suffering from cancer is increasing across the globe. For instance, according to the February 2022 update by the World Health Organization (WHO), cancer accounted for approximately 10 million deaths, worldwide, in 2020. The most common in 2020 (in terms of new cases of cancer) were: breast (2.26 million cases); lung (2.21 million cases); colon and rectum (1.93 million cases); prostate (1.41 million cases); skin (non-melanoma) (1.20 million cases); and stomach (1.09 million cases).
Additionally, the global pharmaceutical companies are investing heavily in the R&D of cancer biologics drugs (monoclonal antibodies), because they are very efficient and non-toxic in the diagnostics and treatment of different types of cancer as compared to chemotherapy and other cancer treatment methods. Moreover, getting approvals for many new cancer monoclonal antibodies by the respective authorities is more efficient and easy. For instance, In January 2021, the antibody-drug conjugate trastuzumab deruxtecan has been granted conditional approval in the European Union for use as a single agent in the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. These advancements may fuel the growth of the cancer monoclonal antibodies segment.
North America is Expected to Dominate the Global Monoclonal Antibodies Market during the Forecast Period
North America is segmented into three countries - the United States, Canada, and Mexico. North America may dominate in the market share of global monoclonal antibodies because of the presence of a standard nationwide healthcare system, especially in the United States and Canada, and huge funding by governments for the R&D of new biological therapies, especially for cancer and new infectious diseases, rising geriatric population and diseases associated with them, and presence of key market players in the region during the forecast period.
Some of the key market players are headquartered in the United States, actively advancing the technique, launching new products, and forming strategic partnerships to have an edge in the monoclonal antibodies market. Several companies and other related organizations are also engaged in the development of monoclonal antibodies and, over the year, had few breakthroughs. For instance, in March 2022, GlaxoSmithKline plc and Vir Biotechnology, Inc. announced that the United States Food and Drug Administration has amended the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab, an investigational monoclonal antibody. Additionally, the increasing cases of chronic diseases, such as cancer, may boost the growth of the market in the region. As per the GLOBOCAN 2020 report, 2,281,658 new cancer cases were diagnosed and 612,390 deaths due to cancer in the United States alone. The cancer cases in Canada and Mexico were 274,364 and 195,499, respectively. These factors are expected to drive the growth of the studied market over the forecast period.
Monoclonal Antibodies Industry Overview
The monoclonal antibodies market is expected to be highly competitive with the number of established companies in the market and the new incoming companies, which are investing heavily in R&D with new and advanced technologies. In the current scenario, COVID-19 and cancer therapeutics are expected to be the major domain of competition between the companies. Some of the major key players of the global monoclonal antibodies market are - Eli Lilly, F Hoffmann-La Roche, Merck, Amgen Inc., and Novartis AG, among others.
Monoclonal Antibodies Market Leaders
-
Merck Group
-
Eli Lilly and Company
-
Amgen Inc.
-
Novartis AG
-
F Hoffmann-La Roche AG
*Disclaimer: Major Players sorted in no particular order
Monoclonal Antibodies Market News
- In February 2022, Eli Lilly and Company announced that United States Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant. Bebtelovimab is a neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2.
- In January 2022, HaemaLogiX Ltd (HaemaLogiX) and Lonza entered into an agreement to manufacture the next clinical batch (cGMP) of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, a monoclonal antibody that binds to a cell surface target called kappa myeloma antigen (KMA) that is only found on myeloma cancer cells and not on normal plasma cells.
Monoclonal Antibodies Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Technological Advancements
- 4.2.2 Increasing Burden of Cancer and Other Chronic Diseases
- 4.2.3 Huge Funding by Government for the Research and Development
-
4.3 Market Restraints
- 4.3.1 High Cost Pertaining to the Method Involved in the Production of Monoclonal Antibodies
- 4.3.2 Loss of Patents
-
4.4 Industry Attractiveness - Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Buyers/Consumers
- 4.4.2 Bargaining Power of Suppliers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Production Methods
- 5.1.1 In Vivo
- 5.1.2 In Vitro
-
5.2 By Source
- 5.2.1 Chimeric
- 5.2.2 Human
- 5.2.3 Humanized
- 5.2.4 Murine
-
5.3 By Indications
- 5.3.1 Cancer
- 5.3.2 Autoimmune Diseases
- 5.3.3 Infectious Diseases
- 5.3.4 Inflammatory Diseases
- 5.3.5 Other Indications
-
5.4 By End Users
- 5.4.1 Hospitals
- 5.4.2 Research Institutes
- 5.4.3 Other End Users
-
5.5 Geography
- 5.5.1 North America
- 5.5.1.1 United States
- 5.5.1.2 Canada
- 5.5.1.3 Mexico
- 5.5.2 Europe
- 5.5.2.1 Germany
- 5.5.2.2 United Kingdom
- 5.5.2.3 France
- 5.5.2.4 Italy
- 5.5.2.5 Spain
- 5.5.2.6 Rest of Europe
- 5.5.3 Asia-Pacific
- 5.5.3.1 China
- 5.5.3.2 Japan
- 5.5.3.3 India
- 5.5.3.4 Australia
- 5.5.3.5 South Korea
- 5.5.3.6 Rest of Asia Pacific
- 5.5.4 Middle-East and Africa
- 5.5.4.1 GCC
- 5.5.4.2 South Africa
- 5.5.4.3 Rest of Middle-East and Africa
- 5.5.5 South America
- 5.5.5.1 Brazil
- 5.5.5.2 Argentina
- 5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Eli Lilly and Company
- 6.1.2 Johnson & Johnson
- 6.1.3 Merck KGaA
- 6.1.4 Pfizer Inc.
- 6.1.5 GlaxoSmithKline PLC
- 6.1.6 Novartis AG
- 6.1.7 AstraZeneca PLC
- 6.1.8 Amgen Inc.
- 6.1.9 AbbVie Inc.
- 6.1.10 Bristol Myers Squibb Co.
- 6.1.11 F. Hoffmann-La-Roche Ltd.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityMonoclonal Antibodies Industry Segmentation
The monoclonal antibodies are cloned from antibodies produced in the body and are used for the treatment of many fatal diseases like cancer, autoimmune diseases, viral disease treatment, and others. The main advantage of using monoclonal antibodies in treating these diseases are they are taken from a biological source and can produce antibodies in the long term. The Monoclonal Antibodies Market is Segmented by Production Methods (In Vivo and In Vitro), Source (Chimeric, Human, Humanized, and Murine), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, and Other Indications), End Users (Hospitals, Research Institutes, and Other End Users), and Geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Production Methods | In Vivo | |
| In Vitro | ||
| By Source | Chimeric | |
| Human | ||
| Humanized | ||
| Murine | ||
| By Indications | Cancer | |
| Autoimmune Diseases | ||
| Infectious Diseases | ||
| Inflammatory Diseases | ||
| Other Indications | ||
| By End Users | Hospitals | |
| Research Institutes | ||
| Other End Users | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Monoclonal Antibodies Market Research FAQs
What is the current Global Monoclonal Antibodies Market size?
The Global Monoclonal Antibodies Market is projected to register a CAGR of 8.51% during the forecast period (2024-2029)
Who are the key players in Global Monoclonal Antibodies Market?
Merck Group, Eli Lilly and Company, Amgen Inc., Novartis AG and F Hoffmann-La Roche AG are the major companies operating in the Global Monoclonal Antibodies Market.
Which is the fastest growing region in Global Monoclonal Antibodies Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Monoclonal Antibodies Market?
In 2024, the North America accounts for the largest market share in Global Monoclonal Antibodies Market.
What years does this Global Monoclonal Antibodies Market cover?
The report covers the Global Monoclonal Antibodies Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Monoclonal Antibodies Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Monoclonal Antibody Therapy Industry Report
Statistics for the 2024 Monoclonal Antibody Therapy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Monoclonal Antibody Therapy analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
